Annual General Meeting of Active Biotech AB LUND,

LUND, Sweden, June 12, 2015 (GLOBE NEWSWIRE) -- The Annual General Meeting of Active Biotech was held on June 11, 2015.

In accordance with the Board of Directors' proposal, it was resolved that no dividend would be paid.

The board members and the managing director were discharged from liability with respect to their management of the company for 2014.

In accordance with the Election Committee's proposal, the Board members Mats Arnhög, Magnhild Sandberg, Peter Sjöstrand and Peter Thelin were re-elected. The Meeting also resolved to re-elect Mats Arnhög as Chairman of the Board. KPMG AB was re-elected as auditor.

Furthermore, in accordance with the Election Committee's proposal, the Meeting resolved that the Election Committee shall be composed of representatives for the three largest owners, as per the end of September, 2015, as well as the Chairman of the Board.

The Meeting approved the Board's proposal concerning guidelines for remuneration to the President and other senior executives. The guidelines essentially conform to the principles applied to date.  

In accordance with the Board's proposal, the Meeting resolved to authorize the Board, for a period that does not extend past the date of the next Annual General Meeting, to resolve on the issue of not more than seven million new shares and/or convertibles with the corresponding dilution effect, with or without pre-emptive rights for the company's shareholders.

Lund, June 12, 2015

Active Biotech AB (publ) Tomas Leanderson President and CEO

For further information, please contact: Hans Kolam, CFO Tel +46 46 19 20 44

Active Biotech AB (publ) (Nasdaq Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an orally administered small molecule with unique immunomodulatory properties, is in pivotal phase III development for the treatment of relapsing remitting multiple sclerosis. Also, laquinimod is in phase II development for the treatment of primary progressive multiple sclerosis and Huntington's disease. Furthermore, commercial activities are ongoing for the projects ISI, ANYARA and paquinimod. Please visit www.activebiotech.com for more information.

Active Biotech AB (Corp. Reg. No. 556223-9227) Box 724, SE-220 07 Lund Tel: +46 46 19 20 00 Fax: +46 46 19 11 00

Active Biotech is obligated to publish the information contained in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act . This information was provided to the media for publication at 8:30 a.m. CET on June 12, 2015.

Annual General Meeting of Active Biotech AB http://hugin.info/1002/R/1927809/692040.pdf

HUG#1927809